Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib
combined with Anlotinib as the first-line treatment in locally advanced or metastatic
non-small cell lung cancer with sensitive EGFR mutations.